Each year, over 15 million patients present to the emergency department (ED) in North America and Europe with suspected acute myocardial infarction (AMI) [1,2]. Clinical practice guidelines highlight the need for rapid diagnosis and risk stratification [1,2]. High-sensitivity cardiac troponin (hs-cTn) assays and hs-cTn-based rapid diagnostic algorithms have revolutionized the early diagnosis of AMI, enabling earlier and more accurate identification of acute myocardial injury [3]. However, while these advancements have improved diagnostic precision, optimal strategies for rapid risk stratification, particularly regarding premature death in patients with non-AMI-related chest pain, remain uncertain, even after initial assessment in the ED.
